PTC Therapeutics, Inc. (PTCT) is a publicly traded Healthcare sector company. As of September 21, 2026, PTCT trades at $65.36 with a market cap of $5.46B and a P/E ratio of -100.55. PTCT moved -3.82% today. Year to date, PTCT is -13.94%; over the trailing twelve months it is +3.96%. Its 52-week range spans $35.95 to $90.87. Analyst consensus is buy with an average price target of $99.50. Rallies surfaces PTCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for PTCT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $65.36 |
| Market Cap | $5.46B |
| P/E Ratio | -100.55 |
| EPS | $-0.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $90.87 |
| 52-Week Low | $35.95 |
| Volume | 850.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.01B |
| Net Income | $-38.38M |
| Gross Margin | 0.00% |
10 analysts cover PTCT: 0 strong buy, 8 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $99.50.